Licensing & partnership
Funnel Biosciences signs AI antibody pact with Third Rock worth up to $2.16B
Funnel Biosciences will apply its epitope-guided AI antibody design platform to several targets chosen by Third Rock Ventures. Funnel gets platform fees and could earn up to about $2.16 billion if set conditions are met; the split of payments was not disclosed. The company claims its system yields picomolar binders without lab affinity maturation.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.